147 related articles for article (PubMed ID: 23627639)
1. Thickness of superficial basal cell carcinoma (sBCC) predicts imiquimod efficacy: a proposal for a thickness-based definition of sBCC.
McKay KM; Sambrano BL; Fox PS; Bassett RL; Chon S; Prieto VG
Br J Dermatol; 2013 Sep; 169(3):549-54. PubMed ID: 23627639
[TBL] [Abstract][Full Text] [Related]
2. Tumor thickness and adnexal extension of superficial basal cell carcinoma (sBCC) as determinants of treatment failure for methylaminolevulinate (MAL)-photodynamic therapy (PDT), imiquimod, and 5-fluorouracil (FU).
Roozeboom MH; van Kleef L; Arits AH; Mosterd K; Winnepenninckx VJ; van Marion AM; Nelemans PJ; Kelleners-Smeets NW
J Am Acad Dermatol; 2015 Jul; 73(1):93-8. PubMed ID: 25935596
[TBL] [Abstract][Full Text] [Related]
3. Confirmation of histological clearance of superficial basal cell carcinoma with multiple serial sectioning and Mohs' micrographic surgery following treatment with imiquimod 5% cream.
Ezughah FI; Affleck AG; Evans A; Ibbotson SH; Fleming CJ
J Dermatolog Treat; 2008; 19(3):156-8. PubMed ID: 18569271
[TBL] [Abstract][Full Text] [Related]
4. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe.
Schulze HJ; Cribier B; Requena L; Reifenberger J; Ferrándiz C; Garcia Diez A; Tebbs V; McRae S
Br J Dermatol; 2005 May; 152(5):939-47. PubMed ID: 15888150
[TBL] [Abstract][Full Text] [Related]
5. Local reactions to imiquimod in the treatment of basal cell carcinoma.
Tandon Y; Brodell RT
Dermatol Online J; 2012 Sep; 18(9):1. PubMed ID: 23031368
[TBL] [Abstract][Full Text] [Related]
6. Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and nonrandomized trials.
Roozeboom MH; Arits AH; Nelemans PJ; Kelleners-Smeets NW
Br J Dermatol; 2012 Oct; 167(4):733-56. PubMed ID: 22612571
[TBL] [Abstract][Full Text] [Related]
7. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion.
Sterry W; Ruzicka T; Herrera E; Takwale A; Bichel J; Andres K; Ding L; Thissen MR
Br J Dermatol; 2002 Dec; 147(6):1227-36. PubMed ID: 12452875
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and satisfaction with imiquimod for the treatment of superficial basal cell carcinoma in daily dermatological practice.
Daudén E;
J Eur Acad Dermatol Venereol; 2011 Nov; 25(11):1304-10. PubMed ID: 21348896
[TBL] [Abstract][Full Text] [Related]
9. Photodynamic therapy vs. topical imiquimod for treatment of superficial basal cell carcinoma: a subgroup analysis within a noninferiority randomized controlled trial.
Roozeboom MH; Nelemans PJ; Mosterd K; Steijlen PM; Arits AH; Kelleners-Smeets NW
Br J Dermatol; 2015 Mar; 172(3):739-45. PubMed ID: 25066012
[TBL] [Abstract][Full Text] [Related]
10. Treatment of all basal cell carcinoma variants including large and high-risk lesions with 5% imiquimod cream: histological and clinical changes, outcome, and follow-up.
Schiessl C; Wolber C; Tauber M; Offner F; Strohal R
J Drugs Dermatol; 2007 May; 6(5):507-13. PubMed ID: 17679185
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Follow-Up Results of Topical Imiquimod Treatment in Basal Cell Carcinoma.
Bostanci S; Kocyigit P; Vural S; Heper AO; Botsali A
Dermatol Surg; 2018 Jan; 44(1):36-41. PubMed ID: 29016542
[TBL] [Abstract][Full Text] [Related]
12. Imiquimod: a review of basal cell carcinoma treatments.
Karve SJ; Feldman SR; Yentzer BA; Pearce DJ; Balkrishnan R
J Drugs Dermatol; 2008 Nov; 7(11):1044-51. PubMed ID: 19110735
[TBL] [Abstract][Full Text] [Related]
13. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe.
Gollnick H; Barona CG; Frank RG; Ruzicka T; Megahed M; Tebbs V; Owens M; Stampone P
Eur J Dermatol; 2005; 15(5):374-81. PubMed ID: 16172048
[TBL] [Abstract][Full Text] [Related]
14. Conventional and combination topical photodynamic therapy for basal cell carcinoma: systematic review and meta-analysis.
Collier NJ; Haylett AK; Wong TH; Morton CA; Ibbotson SH; McKenna KE; Mallipeddi R; Moseley H; Seukeran D; Ward KA; Mohd Mustapa MF; Exton LS; Green AC; Rhodes LE
Br J Dermatol; 2018 Dec; 179(6):1277-1296. PubMed ID: 29889302
[TBL] [Abstract][Full Text] [Related]
15. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma.
Vidal D; Matías-Guiu X; Alomar A
Clin Exp Dermatol; 2004 Sep; 29(5):518-25. PubMed ID: 15347339
[TBL] [Abstract][Full Text] [Related]
16. Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks.
Quirk C; Gebauer K; Owens M; Stampone P
Australas J Dermatol; 2006 Nov; 47(4):258-65. PubMed ID: 17034468
[TBL] [Abstract][Full Text] [Related]
17. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study.
Geisse JK; Rich P; Pandya A; Gross K; Andres K; Ginkel A; Owens M
J Am Acad Dermatol; 2002 Sep; 47(3):390-8. PubMed ID: 12196749
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo.
Urosevic M; Maier T; Benninghoff B; Slade H; Burg G; Dummer R
Arch Dermatol; 2003 Oct; 139(10):1325-32. PubMed ID: 14568837
[TBL] [Abstract][Full Text] [Related]
19. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial.
Peris K; Campione E; Micantonio T; Marulli GC; Fargnoli MC; Chimenti S
Dermatol Surg; 2005 Mar; 31(3):318-23. PubMed ID: 15841634
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of multiple superficial basal cell carcinomas with topical imiquimod: case report and review of the literature.
Drehs MM; Cook-Bolden F; Tanzi EL; Weinberg JM
Dermatol Surg; 2002 May; 28(5):427-9. PubMed ID: 12030878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
